Responses
Editorial
It’s not NICE to discriminate
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 18 May 2017
- Published on: 18 May 2017Should patent costs burden patients?Show More
Dear Editor,
Harris raises important concerns about NICE’s QALY methodology. The rational for rationing treatments is opportunity cost; the alternative better uses of scarce resources. If opportunity cost is king, why does NICE not examine the opportunity cost of drugs, the resources (factor costs) taken to manufacture them, i.e. the ex patent costs rather than the supplier price, in its calculations, certainly wit...
Conflict of Interest:
None declared.
Other content recommended for you
- Ageism and equality
- National Institute for Health and Clinical Excellence appraisal and ageism
- Wickedness or folly? The ethics of NICE’s decisions
- Nice and not so nice
- Whose dignity? Resolving ambiguities in the scope of “human dignity” in the Universal Declaration on Bioethics and Human Rights
- Ethics and opportunity costs: have NICE grasped the ethics of priority setting?
- Not a NICE fallacy: a reply to Dr Quigley
- Justice and the NICE approach
- National Institute for Clinical Excellence and its value judgments
- Tobacco industry’s human rights makeover: an archival review of British American Tobacco’s human rights rhetorical veneer